AFA urges FDA to wait for McNeil raw data on aspirin/alcohol link at "feedback" meeting.
• By The Tan Sheet
AFA URGES FDA TO WAIT FOR McNEIL RAW DATA ON ASPIRIN/ALCOHOL INTERACTION before proposing an alcohol warning on aspirin products. At a July 11 "OTC feedback" meeting, Aspirin Foundation of America outside counsel Bruce Dickson (Washington, D.C. law firm Paul, Hastings, Janofsky & Walker) objected to FDA's plan to require an alcohol warnings on aspirin-containing OTC analgesics ("The Tan Sheet" Jan. 16, p. 3).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.
Bayesian statistics could help clinical trial sponsors to include external information in their analyses, but concerns around bias and incorrect conclusions remain, the European Medicines Agency said.
A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.